Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legislation
|
| gptkbp:aims_to |
encourage the development of drugs for rare diseases
|
| gptkbp:amended_by |
Orphan Drug Amendments of 1985
Orphan Drug Modernization Act of 2017 |
| gptkbp:appointed_by |
gptkb:Food_and_Drug_Administration_(FDA)
|
| gptkbp:defines |
orphan drug as a drug for a disease affecting fewer than 200,000 people
|
| gptkbp:enacted_by |
gptkb:legislation
January 4, 1983 |
| gptkbp:facilitates |
faster approval process for orphan drugs
|
| gptkbp:has_impact_on |
gptkb:Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
Orphan Drug Act
|
| gptkbp:is_considered |
a significant piece of health legislation
|
| gptkbp:is_criticized_for |
potentially high costs of orphan drugs
|
| gptkbp:is_evaluated_by |
health economists
|
| gptkbp:is_influenced_by |
public health needs
|
| gptkbp:is_monitored_by |
FDA's Office of Orphan Products Development
|
| gptkbp:is_part_of |
U. S. public health policy
|
| gptkbp:is_related_to |
rare diseases
|
| gptkbp:is_supported_by |
patient advocacy groups
|
| gptkbp:led_to |
increased investment in rare disease research
|
| gptkbp:provides |
market exclusivity for approved orphan drugs
tax credits for clinical research |
| gptkbp:resulted_in |
the approval of many orphan drugs
|
| gptkbp:bfsParent |
gptkb:U._S._Food_and_Drug_Administration
|
| gptkbp:bfsLayer |
4
|